Rhode Island S2112 requires health plans to cover at least one type of glucagon for hypoglycemia without copayment or deductible.
Rhode Island S2112 mandates that health plans providing prescription benefits must cover at least one type of glucagon, such as an auto-injector or nasal spray, which does not require reconstitution to treat hypoglycemia. The coverage will allow for two glucagon units per year without any copayment or deductible. This requirement will take effect starting January 1, 2027, and health plans may choose to implement this benefit earlier.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.